Incorporating biomarkers into cancer and aging research

Journal of Clinical Oncology

Volumn 32, Issue 24, 2014, Pages 2611-2616

  Hubbard, Joleen M ^a   Cohen, Harvey J ^b   Muss, Hyman B ^c  

^a MAYO CLINIC   (United States)

^b DUKE UNIVERSITY   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; INTERLEUKIN 6; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA;

AGE; CANCER PATIENT; CANCER RESEARCH; CANCER RISK; CANCER THERAPY; CELL AGING; CHRONIC INFLAMMATION; CLINICAL TRIAL (TOPIC); GERIATRIC ASSESSMENT; HUMAN; IMAGING; MALIGNANT NEOPLASTIC DISEASE; MUSCLE MASS; NEOPLASM; ONCOLOGIST; PATIENT; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SARCOPENIA; SENESCENCE; AGING; GERIATRICS; METABOLISM; NEOPLASMS; PROCEDURES;

AGE FACTORS; AGING; GERIATRICS; HUMANS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84906256517     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.4261     Document Type: Review

References (76)

1. Gross CP, McAvay GJ, Guo Z, et al: The impact of chronic illnesses on the use and effectiveness of adjuvant chemotherapy for colon cancer. Cancer 109:2410-2419, 2007 (Pubitemid 46906459)
2. Jatoi A, Hillman S, Stella PJ, et al: Daily activities: Exploring their spectrum and prognostic impact in older, chemotherapy-treated lung cancer patients. Support Care Cancer 11:460-464, 2003 (Pubitemid 36869952)
3. Muss HB, Woolf S, Berry D, et al: Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 293: 1073-1081, 2005 (Pubitemid 40300281)
4. Sargent DJ, Goldberg RM, Jacobson SD, et al: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345:1091-1097, 2001
5. Kornblith AB, Kemeny M, Peterson BL, et al: Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials. Cancer 95:989-996, 2002 (Pubitemid 34925347)
6. Jessup JM, Stewart A, Greene FL, et al: Adjuvant chemotherapy for stage III colon cancer: Implications of race/ethnicity, age, and differentiation. JAMA 294:2703-2711, 2005 (Pubitemid 41770099)
7. Smith BD, Jiang J, McLaughlin SS, et al: Improvement in breast cancer outcomes over time: Are older women missing out? J Clin Oncol 29: 4647-4653, 2011
8. Mitnitski AB, Graham JE, Mogilner AJ, et al: Frailty, fitness and late-life mortality in relation to chronological and biological age. BMC Geriatr 2:1, 2002
9. Fried LP, Tangen CM, Walston J, et al: Frailty in older adults: Evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56:M146-M156, 2001 (Pubitemid 32187141)
10. Cesari M, Penninx BW, Pahor M, et al: Inflammatory markers and physical performance in older persons: The In CHIANTI study. J Gerontol A Biol Sci Med Sci 59:242-248, 2004 (Pubitemid 38375337)
11. Ferrucci L, Cavazzini C, Corsi A, et al: Biomarkers of frailty in older persons. J Endocrinol Invest 25:10-15, 2002
12. Hubbard RE, O'Mahony MS, Savva GM, et al: Inflammation and frailty measures in older people. J Cell Mol Med 13:3103-3109, 2009
13. Leng SX, Xue QL, Tian J, et al: Inflammation and frailty in older women. J Am Geriatr Soc 55:864-871, 2007 (Pubitemid 47011043)
14. Walston J, McBurnie MA, Newman A, et al: Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: Results from the Cardiovascular Health Study. Arch Intern Med 162:2333-2341, 2002 (Pubitemid 35332516)
15. Cohen HJ, Harris T, Pieper CF: Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. Am J Med 114:180-187, 2003 (Pubitemid 36294002)
16. de Saint-Hubert M, Jamart J, Morrhaye G, et al: Serum IL-6 and IGF-1 improve clinical prediction of functional decline after hospitalization in older patients. Aging Clin Exp Res 23:106-111, 2011
17. Huffman KM, Pieper CF, Kraus VB, et al: Relations of a marker of endothelial activation (s-VCAM) to function and mortality in communitydwelling older adults. J Gerontol A Biol Sci Med Sci 66:1369-1375, 2011
18. Puts MT, Visser M, Twisk JW, et al: Endocrine and inflammatory markers as predictors of frailty. Clin Endocrinol (Oxf) 63:403-411, 2005 (Pubitemid 41442334)
19. Reuben DB, Cheh AI, Harris TB, et al: Peripheral blood markers of inflammation predict mortality and functional decline in high-functioning communitydwelling older persons. J Am Geriatr Soc 50:638-644, 2002 (Pubitemid 34298751)
20. Rønning B, Wyller TB, Seljeflot I, et al: Frailty measures, inflammatory biomarkers and postoperative complications in older surgical patients. Age Ageing 39:758-761, 2010
21. Cawthon RM, Smith KR, O'Brien E, et al: Association between telomere length in blood and mortality in people aged 60 years or older. Lancet 361:393-395, 2003 (Pubitemid 36164975)
22. Epel ES, Merkin SS, Cawthon R, et al: The rate of leukocyte telomere shortening predicts mortality from cardiovascular disease in elderly men. Aging (Albany NY) 1:81-88, 2008
23. Farzaneh-Far R, Cawthon RM, Na B, et al: Prognostic value of leukocyte telomere length in patients with stable coronary artery disease: Data from the Heart and Soul Study. Arterioscler Thromb Vasc Biol 28:1379-1384, 2008
24. Risques RA, Arbeev KG, Yashin AI, et al: Leukocyte telomere length is associated with disability in older U.S. population. J Am Geriatr Soc 58:1289-1298, 2010
25. Krishnamurthy J, Torrice C, Ramsey MR, et al: Ink4a/Arf expression is a biomarker of aging. J Clin Invest 114:1299-1307, 2004 (Pubitemid 40385301)
26. Liu Y, Sanoff HK, Cho H, et al: Expression of p16(INK4a) in peripheral blood T-cells is a biomarker of human aging. Aging Cell 8:439-448, 2009
27. Song Z, von Figura G, Liu Y, et al: Lifestyle impacts on the aging-associated expression of biomarkers of DNA damage and telomere dysfunction in human blood. Aging Cell 9:607-615, 2010
28. Baumgartner RN, Koehler KM, Gallagher D, et al: Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 147:755-763, 1998 (Pubitemid 28183275)
29. Heymsfield SB, Wang Z, Baumgartner RN, et al: Human body composition: Advances in models and methods. Annu Rev Nutr 17:527-558, 1997 (Pubitemid 27328812)
30. Janssen I, Heymsfield SB, Ross R: Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc 50:889-896, 2002 (Pubitemid 34496687)
31. Metter EJ, Talbot LA, Schrager M, et al: Skeletal muscle strength as a predictor of all-cause mortality in healthy men. J Gerontol A Biol Sci Med Sci 57:B359-B365, 2002
32. Kanapuru B, Ershler WB: Inflammation, coagulation, and the pathway to frailty. Am J Med 122:605-613, 2009
33. Robson SC, Shephard EG, Kirsch RE: Fibrin degradation product D-dimer induces the synthesis and release of biologically active IL-1 beta, IL-6 and plasminogen activator inhibitors from monocytes in vitro. Br J Haematol 86:322-326, 1994 (Pubitemid 24198995)
34. Carter RA, Wicks IP: Vascular cell adhesion molecule 1 (CD106): A multifaceted regulator of joint inflammation. Arthritis Rheum 44:985-994, 2001 (Pubitemid 32433601)
35. Ershler WB, Sun WH, Binkley N, et al: Interleukin-6 and aging: Blood levels and mononuclear cell production increase with advancing age and in vitro production is modifiable by dietary restriction. Lymphokine Cytokine Res 12:225-230, 1993 (Pubitemid 23264834)
36. Sindermann J, Kruse A, Frercks HJ, et al: Investigations of the lymphokine system in elderly individuals. Mech Ageing Dev 70:149-159, 1993
37. Fagiolo U, Cossarizza A, Scala E, et al: Increased cytokine production in mononuclear cells of healthy elderly people. Eur J Immunol 23:2375-2378, 1993 (Pubitemid 23265910)
38. Cushman M, Psaty BM, Macy E, et al: Correlates of thrombin markers in an elderly cohort free of clinical cardiovascular disease. Arterioscler Thromb Vasc Biol 16:1163-1169, 1996 (Pubitemid 26299289)
39. Bruunsgaard H, Pedersen M, Pedersen BK: Aging and proinflammatory cytokines. Curr Opin Hematol 8:131-136, 2001 (Pubitemid 32324632)
40. Franceschi C, Capri M, Monti D, et al: Inflammaging and anti-inflammaging: A systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev 128:92-105, 2007 (Pubitemid 46073065)
41. Vasto S, Candore G, Balistreri CR, et al: Inflammatory networks in ageing, age-related diseases and longevity. Mech Ageing Dev 128:83-91, 2007 (Pubitemid 46073064)
42. Pieper CF, Rao KM, Currie MS, et al: Age, functional status, and racial differences in plasma D-dimer levels in community-dwelling elderly persons. J Gerontol A Biol Sci Med Sci 55:M649-M657, 2000 (Pubitemid 32010310)
43. Yao X, Li H, Leng SX: Inflammation and immune system alterations in frailty. Clin Geriatr Med 27:79-87, 2011
44. De Martinis M, Franceschi C, Monti D, et al: Inflammation markers predicting frailty and mortality in the elderly. Exp Mol Pathol 80:219-227, 2006
45. Ferrucci L, Harris TB, Guralnik JM, et al: Serum IL-6 level and the development of disability in older persons. J Am Geriatr Soc 47:639-646, 1999 (Pubitemid 29266628)
46. Ferrucci L, Penninx BW, Volpato S, et al: Change in muscle strength explains accelerated decline of physical function in older women with high interleukin-6 serum levels. J Am Geriatr Soc 50:1947-1954, 2002 (Pubitemid 35462439)
47. Goodman MN: Interleukin-6 induces skeletal muscle protein breakdown in rats. Proc Soc Exp Biol Med 205:182-185, 1994 (Pubitemid 24130273)
48. Todorov P, Cariuk P, McDevitt T, et al: Characterization of a cancer cachectic factor. Nature 379:739-742, 1996 (Pubitemid 26061738)
49. Mitch WE, Goldberg AL: Mechanisms of muscle wasting: The role of the ubiquitin-proteasome pathway. N Engl J Med 335:1897-1905, 1996 (Pubitemid 26419198)
50. Falandry C, Gilson E, Rudolph KL: Are aging biomarkers clinically relevant in oncogeriatrics? Crit Rev Oncol Hematol 85:257-265, 2013
51. Panju AH, Danesh A, Minden MD, et al: Associations between quality of life, fatigue, and cytokine levels in patients aged 50+ with acute myeloid leukemia. Support Care Cancer 17:539-546, 2009
52. Rich T, Innominato PF, Boerner J, et al: Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour restactivity patterns in patients with metastatic colorectal cancer. Clin Cancer Res 11:1757-1764, 2005 (Pubitemid 40471837)
53. Rao AV, Valk PJ, Metzeler KH, et al: Agespecific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia. J Clin Oncol 27:5580-5586, 2009
54. Campisi J: Senescent cells, tumor suppression, and organismal aging: Good citizens, bad neighbors. Cell 120:513-522, 2005 (Pubitemid 40269765)
55. Collado M, Blasco MA, Serrano M: Cellular senescence in cancer and aging. Cell 130:223-233, 2007 (Pubitemid 47081143)
56. Coppé JP, Patil CK, Rodier F, et al: Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 6:2853-2868, 2008
57. Freund A, Orjalo AV, Desprez PY, et al: Inflammatory networks during cellular senescence: Causes and consequences. Trends Mol Med 16:238-246, 2010
58. Hemann MT, Strong MA, Hao LY, et al: The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell 107:67-77, 2001 (Pubitemid 32972038)
59. Mather KA, Jorm AF, Parslow RA, et al: Is telomere length a biomarker of aging? A review. J Gerontol A Biol Sci Med Sci 66:202-213, 2011
60. Pallis AG, Hatse S, Brouwers B, et al: Evaluating the physiological reserves of older patients with cancer: The value of potential biomarkers of aging? J Geriatr Oncol 5:204-218, 2014
61. Harley CB, Futcher AB, Greider CW: Telomeres shorten during ageing of human fibroblasts. Nature 345:458-460, 1990
62. Jiang H, Schiffer E, Song Z, et al: Proteins induced by telomere dysfunction and DNA damage represent biomarkers of human aging and disease. Proc Natl Acad Sci U S A 105:11299-11304, 2008
63. Campisi J: Cellular senescence as a tumorsuppressor mechanism. Trends Cell Biol 11:S27-S31, 2001
64. Brown JP, Wei W, Sedivy JM: Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. Science 277: 831-834, 1997 (Pubitemid 27366737)
65. Muss HB, Krishnamurthy J, Alston SM, et al: P16INK4a expression after chemotherapy in older women with early-stage breast cancer. J Clin Oncol 29:550s, 2011 (suppl; abstr 9002)
66. Roubenoff R: Sarcopenia: Effects on body composition and function. J Gerontol A Biol Sci Med Sci 58:1012-1017, 2003 (Pubitemid 37467299)
67. Baumgartner RN, Wayne SJ, Waters DL, et al: Sarcopenic obesity predicts instrumental activities of daily living disability in the elderly. Obes Res 12:1995-2004, 2004
68. Zoico E, Roubenoff R: The role of cytokines in regulating protein metabolism and muscle function. Nutr Rev 60:39-51, 2002 (Pubitemid 34131000)
69. Schrager MA, Metter EJ, Simonsick E, et al: Sarcopenic obesity and inflammation in the In CHIANTI study. J Appl Physiol 102:919-925, 2007 (Pubitemid 46377013)
70. Prado CM, Lieffers JR, McCargar LJ, et al: Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: A populationbased study. Lancet Oncol 9:629-635, 2008
71. Prado CM, Birdsell LA, Baracos VE: The emerging role of computerized tomography in assessing cancer cachexia. Curr Opin Support Palliat Care 3:269-275, 2009
72. Prado CM, Baracos VE, McCargar LJ, et al: Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 13:3264-3268, 2007 (Pubitemid 46944911)
73. Baigrie RJ, Lamont PM, Kwiatkowski D, et al: Systemic cytokine response after major surgery. Br J Surg 79:757-760, 1992
74. Wirtz DC, Heller KD, Miltner O, et al: Interleukin- 6: A potential inflammatory marker after total joint replacement. Int Orthop 24:194-196, 2000
75. Mueller S, Fullerton HJ, Stratton K, et al: Radiation, atherosclerotic risk factors, and stroke risk in survivors of pediatric cancer: A report from the Childhood Cancer Survivor Study. Int J Radiat Oncol Biol Phys 86:649-655, 2013
76. Armstrong GT, Liu Q, Yasui Y, et al: Late mortality among 5-year survivors of childhood cancer: A summary from the Childhood Cancer Survivor Study. J Clin Oncol 27:2328-2338, 2009